中国医药科学杂志欢迎您.   今天是:        
文清华,刘斯颖,吴松珊,黄秀梅.不同剂量米非司酮联合宫瘤清胶囊治疗子宫肌瘤的临床观察[J].中国医药科学,2021,(4):84-86        基金项目:
不同剂量米非司酮联合宫瘤清胶囊治疗子宫肌瘤的临床观察
Clinical observation of different dosages of mifepristone combined with Gongliuqing Capsule in the treatment of uterine fibroids
  
DOI:
中文关键词:  [关键词] 子宫肌瘤;米非司酮;宫瘤清胶囊;剂量
英文关键词:[Key words] Uterine fibroids; Mifepristone; Gongliuqing Capsule; Dosage
作者单位
文清华,刘斯颖,吴松珊,黄秀梅 广东省廉江市人民医院妇产科,广东廉江 524400 
摘要点击次数: 13
全文下载次数: 20
中文摘要:
      [摘要] 目的 探讨不同剂量米非司酮联合宫瘤清胶囊治疗子宫肌瘤的效果。 方法 将2018年2月至2020年2月在廉江市人民医院诊治的104例子宫肌瘤患者随机分为观察组和对照组。观察组给予12.5 mg/d米非司酮联合宫瘤清胶囊治疗,对照组给予25 mg/d米非司酮联合宫瘤清胶囊治疗。比较两组的疗效、性激素水平、子宫体积、子宫肌瘤体积和不良反应。 结果 观察组和对照组的治疗总有效率分别为88.5%和94.2%。治疗3个月后与治疗前相比,两组的促卵泡生成激素(FSH)、促黄体生成素(LH)、雌二醇(E2)、孕酮(P)的浓度均明显低,子宫体积和子宫肌瘤体积均明显小(P<0.01),但疗效,FSH、LH、E2和P的浓度,子宫体积,子宫肌瘤体积在两组间的差异均无统计学意义(P>0.05)。观察组不良反应总发生率明显低于对照组(P<0.05)。 结论 12.5 mg/d或25 mg/d米非司酮联合宫瘤清胶囊治疗子宫肌瘤的疗效相当,但12.5 mg/d米非司酮联合宫瘤清胶囊方案的不良反应发生率更低。
英文摘要:
      [Abstract] Objective To explore the effect of different dosages of mifepristone combined with Gongliuqing Capsule on uterine fibroids. Methods A total of 104 patients with uterine fibroids treated in our hospital from February 2018 to February 2020 were randomly divided into the observation group and the control group. The observation group was given 12.5 mg/d mifepristone combined with Gongliuqing Capsule, while the control group was given 25 mg/d mifepristone combined with Gongliuqing Capsule. The curative effect, sex hormone level, the size of uterine, the size of uterine fibroids and adverse reactions of the two groups were compared. Results The total effective rates of the observation group and the control group were 88.5% and 94.2%, respectively. Three months after the treatment, the concentrations of FSH, LH, E and 2P in the two groups were significantly lower, and the uterine and the uterine fibroids were significantly smaller as compared with those before treatment (P < 0.01). However, there was no significant difference in curative effect, concentration of FSH, LH, E and P, the size of uterine, the size of uterine fibroids between the two groups (P>0.05). The total incidence of 2adverse reactions in the observation group was significantly lower than that in the control group (P<0.05). Conclusion The efficacy of 12.5 mg/d mifepristone combined with Gongliuqing Capsule is equivalent to that of 25 mg/d mifepristone combined with Gongliuqing Capsule in the treatment of uterine fibroids, but the 12.5 mg/d mifepristone combined with Gongliuqing capsule has a lower adverse reaction rate.
查看全文  查看/发表评论  下载PDF阅读器
关闭
关键词: 中国医药科学 中国医学 中国医学科学 中华医学 医学杂志 临床医学杂志 医学期刊 中国预防医学 中华预防医学 预防医学杂志 中国药学 药学杂志
药理杂志 中国中医 中医杂志 中华中医药 中医药杂志 中国医疗 医疗器械杂志 中国中西医结合 中国医药 医药杂志 医药期刊 医药论文 医学论文 科研论文 职称论文
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=3C06DB566315F8DCEE2AF20477E2299008C6CFBF09D6B2F6F10682A8DBBB2FB466E8A9BF29BAD8E68AD413306B59B815695D10FD32EF692E686099615C89549D2527A74D21591B5FBE7FEF650D9DA27F5814695EB1E582CE5CDC7F9390EB44C3C0E4EEDC3C2DC25426494049B347E7E93DEE667EC42139701FDCCAA6F76D9586F55BA9F466D5A4C3&pcid=&cid=&jid=&yid=9475FABC7A03F4AB&aid=&vid=&iid=E158A972A605785F&sid=656F8C8401D91023&eid=7AA74D31F1FF2DCE&fileno=20210221&flag=1&is_more=0">